Lunai Bioworks has retained American Defense International, a Washington, D.C.-based consulting and government affairs firm specializing in defense and national security. This collaboration is designed to support U.S. government agencies in the development of advanced countermeasures against chemical and biological weapons, including highly toxic agents such as sarin nerve gas. Lunai and ADI will work together to position Lunai’s proprietary AI-enabled biomedical data platforms as key assets in identifying, testing, and accelerating the development of protective and therapeutic responses to emerging national security threats.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RENB:
- Renovaro BioSciences to change corporate name to ‘Lunai Bioworks’
- Renovaro Biosciences Granted Nasdaq Compliance Extension
- Renovaro BioSciences secures multiple U.S. patents in biomedical AI
- Renovaro Biosciences Chairman Announces Resignation
- Renovaro BioSciences announces publication of study on dendritic cell therapy